Loading the latest PSX data…
Loading the latest PSX data…
Haleon Pakistan LimitedShariah-compliantKSE-100
−4.41 (−0.63%) today
Live, checked 0s agoThe Haleon Pakistan share price was Rs 692.69 (−0.63%) at the last PSX update (Nov 16, 2026 1:03 PM). HALEON is a pharmaceuticals stock in the KSE-100 index with a market value of Rs 81.1bn.
Last session's range13 Nov 2026
686.5045% up the range700.12
52-week range
650.0012% up the range1,010.00
Price limits (circuit breakers)
627.3947% up the range766.81
HALEON ranks better than 67% of the 304 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
−11.2% over 6M
Daily bars from PSX's end-of-day market summary; today's candle is provisional, from the live price (no volume until the close). Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen HALEON chart with levelsDownload HALEON price history (CSV)Compare HALEON with GLAXO
From daily closes to 2026-11-13. A description of the trend, not a forecast.
Trend reading
Mixed
Down3 up · 3 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 680.95 | 689.03 | 694.57 | 702.65 | 708.19 |
+437.1% over 5 years
Monthly closing prices from the PSX Data Portal, since 2023.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 29 Oct 16:25 | 9 months to 30 Sept | None | Rs 4,728.4m | 40.40 | – |
| 27 Aug 15:11 | Half year to 30 Jun | First interim cash dividend 100% | Rs 3,201.0m | 27.35 | 8 Sept – 9 Sept |
| 30 Apr 10:13 | 1st quarter to 31 Mar | None | Rs 1,524.8m | 13.03 | – |
Measured from October 2021 to October 2026 using PSX daily closes.
For comparison, the KSE-100 (which includes reinvested dividends) returned about 30.5% a year over the same five years, an unusually strong period. Past returns do not predict future ones.
| Measure | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales growth | +15.9% | +17.7% | +14.9% | – |
| Profit growth | +39.2% | +359.9% | +205.9% | – |
| EPS growth | +39.2% | +359.6% | +206.1% | – |
| Net margin | 14.8% | 12.3% | 3.1% | 1.2% |
| Measure | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales growth | −5.4% | – | – | – |
| Profit growth | −5.4% | – | – | – |
| EPS growth | −5.4% | – | – | – |
| Net margin | 15.3% | 16.6% | 15.9% | 15.3% |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales | Rs 43.1bn | Rs 37.2bn | Rs 31.6bn | Rs 27.5bn |
| Profit after tax | Rs 6.4bn | Rs 4.6bn | Rs 996m | Rs 325m |
| Earnings per share (Rs) | 54.45 | 39.11 | 8.51 | 2.78 |
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales | Rs 10.0bn | Rs 10.1bn | Rs 9.6bn | Rs 10.6bn |
| Profit after tax | Rs 1.5bn | Rs 1.7bn | Rs 1.5bn | Rs 1.6bn |
| Earnings per share (Rs) | 13.05 | 14.32 | 13.03 | 13.80 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross margin | 39.1% | 34.5% | 20.4% | 17.4% |
| Net margin | 14.8% | 12.3% | 3.2% | 1.2% |
| EPS growth | 39.2% | 359.6% | 206.1% | -84.8% |
| PEG | 0.39 | 0.06 | 0.10 | -0.70 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2026) EPS fell 5.4% from the same quarter a year earlier.
| Measure | HALEON | Sector median | Reading |
|---|---|---|---|
| P/E | 12.4 | 12.2 | Dearer than peers |
| Dividend yield | 3.6% | 5.2% | Below peers |
| Net margin | 14.8% | 8.8% | Above peers |
| EPS growth | +39.2% | +28.2% | Above peers |
| 1-year return | −14.8% | −14.4% | Below peers |
Sector P/E check. At the sector's median P/E of 12.2, last year's EPS of Rs 54.45 would price HALEON at about Rs 666.63 (−4% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for HALEON (Graham, Lynch, DCF)HALEON pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your HALEON dividend income after tax
| Announced | Period to | Payout | Cash per share | Books closed |
|---|---|---|---|---|
| 27 Aug 2026 | 30 Jun 2026 | First interim cash dividend 100% | Rs 10.00 | 8 Sept 2026 – 9 Sept 2026 |
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
3rd of 18
Rs 81.1bn
P/E (cheapest first)
8th of 13
12.4
Dividend yield
6th of 7
3.6%
1-year return
8th of 15
-14.8%
EPS growth
7th of 15
39.2%
Net margin
3rd of 16
14.8%
danioPSX score
4th of 13
67/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 107.9bn | +0.77% | 9.8 | 6.1% | −14.9% | 88 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.6bn | +0.69% | 10.6 | 4.4% | −6.9% | 82 |
| HALEONThis stock · Haleon Pakistan Limited | Rs 81.1bn | −0.63% | 12.4 | 3.6% | −14.8% | 67 |
| HINOONHighnoon Laboratories Limited | Rs 51.0bn | +0.25% | 12.4 | 5.4% | −14.0% | 79 |
| SEARLThe Searle Company Limited | Rs 47.0bn | +0.90% | 12.1 | – | −24.6% | 53 |
| AGPAGP Limited | Rs 43.8bn | +0.02% | 24.5 | 5.1% | −16.1% | 50 |
| HPLHoechst Pakistan Limited | Rs 38.6bn | +0.22% | 11.0 | 6.9% | −2.3% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.9bn | +0.83% | 23.1 | 1.6% | −7.1% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.6bn | +0.58% | 17.9 | – | −22.6% | 32 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| MACTERMacter International Limited | Rs 12.1bn | +0.93% | 3.8 | – | −26.7% | 52 |
| BFBIOBF Biosciences Limited | Rs 12.1bn | +1.36% | 18.4 | – | −10.8% | 47 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.3bn | −1.17% | 10.8 | – | +33.5% | 64 |
| LIVENLiven Pharma Limited | Rs 4.9bn | +10.00% | – | – | −18.9% | 9 |
Swipe the table sideways for more columns.
No director or substantial-shareholder trades in HALEON read from PSX notices yet.
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Haleon Pakistan Limited (formerly known as GlaxoSmithKline Consumer Healthcare Pakistan Limited) was incorporated in Pakistan as a public listed company under the provisions of the repealed Companies Ordinance, 1984 (now Companies Act, 2017) on 31 March 2015. The Company is a subsidiary of ‘Haleon Netherlands B.V’. The ultimate parent of the Company is Haleon plc. The Company is inter alia principally engaged in the manufacturing, marketing and sale of consumer healthcare and over the counter health products.
Where the price sits in its 52-week range
Low 650.0012% of the way upHigh 1,010.00
Data: PSX Data Portal (Nov 16, 2026 1:03 PM); company data refreshed 16 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell HALEON. Official PSX page for HALEON